A Multicenter Randomized Open-label Study of Oseltamivir Combined With

Status Completed

Clinical Trial Summary

Oseltamivirphosphate is hydrolysed to its active metabolite-the free carboxylate of oseltamivir. Oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor of the activity of the viral neuraminidase (NA) enzyme upon sialic acid, found on glycoproteins on the surface of platelets. By blocking the activity of the enzyme, oseltamivir may prevent platelet destruction in liver.The project was undertaking by Qilu Hospital of Shandong University and other 4 well-known hospitals in China. In order to report the efficacy and safety of oseltamivirphosphate combined with high-dose dexamethasone for the treatment of immune thrombocytopenia (ITP) with high platelet desialylation level, compared to high-dose dexamethasone therapy.

Clinical Trial Description

The investigators are undertaking a parallel group, multicentre, randomised controlled trial of 50 newly diagnosed ITP adult patients with high platelet desialylation level from 5 medical centers in China. One part of the participants are randomly selected to receiver HD-DXM (orally at 40 mg daily for 4d) combined with oseltamivir (orally at 75 mg twice for 10d), the others are selected to receive HD-DXM (orally at 40 mg daily for 4d ) alone. If platelet counts remained <30×109/L or there were bleeding symptoms by day 10, another 4-day course of HD-DXM was given (days 10-14).For the combination arm, patients with an initial response relapsed during the follow-up period, oseltamivir retreatment could be given for another 10 days at the discretion of the physician's advice and patients' will.

Platelet count, bleeding , platelet desialylation level and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. In order to report the efficacy and safety of oseltamivirphosphate combining with high-dose dexamethasone therapy compared to high-dose dexamethasone for the treatment of adults with newly diagnosed ITP . ;

Study Design

Related Conditions & MeSH terms

Thrombocytopenia

Clinical Trial Details

NCT number	NCT01965626
Study type	Interventional
Source	Shandong University
Contact
Status	Completed
Phase	Phase 2
Start date	February 1, 2016
Completion date	May 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04003220` - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed	`NCT02948283` - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia	Phase 1
Recruiting	`NCT03633019` - High-dose Use of rhTPO in CIT Patients	Phase 4
Recruiting	`NCT06087198` - Clinical Performance Evaluation of T-TAS®01 HD Chip
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Active, not recruiting	`NCT03688191` - Study of Sirolimus in CTD-TP in China	Phase 4
Completed	`NCT02845609` - Efficacy of Sialic Acid GNE Related Thrombocytopenia	Phase 2
Recruiting	`NCT02244658` - Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia	Phase 3
Recruiting	`NCT02241031` - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia	Phase 2/Phase 3
Unknown status	`NCT01196884` - Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Completed	`NCT01356576` - Effect of Hemodialysis Membranes on Platelet Count	N/A
Terminated	`NCT01368211` - Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)	Phase 2/Phase 3
Completed	`NCT00039858` - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Phase 4
Completed	`NCT00787241` - Platelet Count Trends in Pre-eclamptic Parturients	N/A
Completed	`NCT00001533` - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine	Phase 1
Not yet recruiting	`NCT06036966` - The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients	Phase 2
Completed	`NCT01791101` - Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.	Phase 2
Recruiting	`NCT06053021` - Antiplatelet Therapy for AIS Patients With Thrombocytopenia	N/A
Recruiting	`NCT03701217` - Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML	Phase 2/Phase 3
Not yet recruiting	`NCT05958511` - Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms